Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 16/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 14/20 | 0.58 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.58 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.55 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425626 | 0.98 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL3931694 | 0.94 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL423453 | 0.83 | POLB (0.58) | L3MBTL3L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL6806463 | 0.83 | L3MBTL3 (0.61) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL920191 | 0.83 | L3MBTL3 (0.61) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL4669817 | 0.81 | POLB (0.50) | L3MBTL3L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL3155682 | 0.81 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL920485 | 0.81 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL27598275 | 0.80 | L3MBTL3 (0.60) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL5367594 | 0.79 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101490058-A | Antiviral agents | GENELABS TECH INC (US) | 2009-07-22 | — | — | CN | claimed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | claimed |
| CN-101103026-A | Bicyclic heteroaryl derivatives for treating viruses | GENELABS INC (US) | 2008-01-09 | — | — | CN | claimed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | claimed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| CN-116327950-A | Use of a composition for the treatment of neuropsychiatric symptoms of neurodegenerative diseases | 阿泽范药品公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116139282-A | Compositions and methods for treating neurodegenerative diseases | 阿泽范药品公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-106459021-B | Compositions and methods for treating neurodegenerative diseases | 阿泽范药品公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| CN-101528741-A | Polycyclic viral inhibitors | GENELABS TECH INC (US) | 2009-09-09 | — | — | CN | disclosed |
| CN-101490058-A | Antiviral agents | GENELABS TECH INC (US) | 2009-07-22 | — | — | CN | disclosed |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. | 2008-02-21 | — | — | US | disclosed |
| CN-101103026-A | Bicyclic heteroaryl derivatives for treating viruses | GENELABS INC (US) | 2008-01-09 | — | — | CN | disclosed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1688420-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2006-08-09 | — | — | EP | disclosed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | GTF3C5, ZC3HAV1, POLI | L3MBTL3 4256/4885L3MBTL1 4165/4885MBTD1 2981/4885 |
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | EIF2AK2, ZC3HAV1, MAVS | L3MBTL3 3912/4885L3MBTL1 3920/4885MBTD1 3913/4885 |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | GTF3C5, ZC3HAV1, POLI | L3MBTL3 4256/4885L3MBTL1 4165/4885MBTD1 2981/4885 |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | L3MBTL3 1385/4885L3MBTL1 1887/4885MBTD1 3051/4885 |
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | L3MBTL3 2698/4885L3MBTL1 3239/4885MBTD1 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.